文献速递性腺与生殖内分泌肥胖与代谢综合征

口服避孕药与生活方式干预对PCOS患者肠促胰岛素及TGF-β超家族激素的影响

Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ß Superfamily Hormones in PCOS.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该研究为一项随机对照试验的二次分析,比较连续口服避孕药(OCP)、强化生活方式干预或两者联合治疗16周对PCOS患者生殖/代谢激素的影响。结果显示OCP显著抑制激活素A、抑制素A、AMH并升高卵泡抑素,同时降低IGF-1、IGFBP-2、胰高血糖素、GLP-2和胃泌酸调节素,而生活方式干预对上述指标无显著影响;激素变化与活产无关,仅激活素A变化与排卵相关。

要点

  • OCP显著抑制胃泌酸调节素(几何均值比0.09,95%CI 0.05-0.18,P<0.001)。
  • 生活方式干预对所列激素指标均无显著影响。
  • 激素变化与活产无关,仅激活素A变化与排卵相关(RR 6.0,95%CI 2.2-16.2,P<0.001)。

核心结论

  • 在PCOS女性中,OCP而非生活方式干预广泛影响生殖/代谢激素,但治疗反应与活产不相关。

研究设计与样本

  • 随机对照试验的二次分析,比较三种16周孕前干预:连续OCP(N=34)、强化生活方式(N=31)或两者联合(N=29)。

主要发现

  • OCP使用与激活素A、抑制素A和AMH显著抑制及FST显著升高相关。
  • OCP使用后IGF-1、IGFBP-2、胰高血糖素和GLP-2水平显著降低。
  • 胃泌酸调节素被OCP强烈抑制(几何均值比0.09,95%CI 0.05-0.18,P<0.001)。
  • 生活方式干预未显著影响任何分析物,联合干预效果与OCP单用相似但减弱。
  • 胃泌酸调节素与总卵巢体积变化正相关(rs=0.27,95%CI 0.03-0.48,P=0.03),与胰岛素敏感性指数正相关(rs=0.48,95%CI 0.27-0.64,P<0.001),与AUC葡萄糖变化负相关(rs=-0.38,95%CI -0.57至-0.16,P=0.001)。

临床怎么用

  • OCP可广泛改变PCOS患者的生殖/代谢激素谱,但不应期望这些变化直接改善活产。
  • 生活方式干预对所列激素无显著影响,临床决策应结合其他获益。
  • 胃泌酸调节素与卵巢体积、胰岛素敏感性及血糖变化相关,或可作为代谢监测的参考指标。

局限性

  • 研究为二次分析,样本量较小(各组29-34例)。
  • 仅评估16周短期干预效果,长期影响未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the effects of common treatments for polycystic ovary syndrome (PCOS) on a panel of hormones (reproductive/metabolic). DESIGN: Secondary analysis of blood from a randomized controlled trial of three 16-week preconception interventions designed to improve PCOS-related abnormalities: continuous oral contraceptive pills (OCPs, N = 34 subjects), intensive lifestyle modification (Lifestyle, N = 31), or a combination of both (Combined, N = 29). MATERIALS AND METHODS: Post-treatment levels of activin A and B, inhibin B, and follistatin (FST), as well as Insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 2 (IGFBP-2), glucagon, glucagon-like peptide 1 (GLP-1) and 2, and oxyntomodulin were compared to baseline, and the change from baseline in these parameters were correlated with outcomes. RESULTS: Oral contraceptive pill use was associated with a significant suppression in activin A, inhibin A, and anti-mullerian hormone (AMH), but a significant increase in FST. IGF-1, IGFBP-2, glucagon, and GLP-2 levels were significantly decreased. Oxyntomodulin was profoundly suppressed by OCPs (ratio of geometric means: 0.09, 95% confidence interval [CI]: 0.05, 0.18, P < 0.001). None of the analytes were significantly affected by Lifestyle, whereas the effects of Combined were similar to OCPs alone, although attenuated. Oxyntomodulin was significantly positively associated with the change in total ovarian volume (rs = 0.27; 95% CI: 0.03, 0.48; P = 0.03) and insulin sensitivity index (rs = 0.48; 95% CI: 0.27, 0.64; P < 0.001), and it was inversely correlated with change in area under the curve (AUC) glucose [rs = -0.38; 95% CI: -0.57, -0.16; P = 0.001]. None of the hormonal changes were associated with live birth, only Activin A was associated with ovulation (risk ratio per 1 ng/mL increase in change in Activin A: 6.0 [2.2, 16.2]; P < 0.001). CONCLUSIONS: In women with PCOS, OCPs (and not Lifestyle) affect a wide variety of reproductive/metabolic hormones, but their treatment response does not correlate with live birth.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Shah A, Dodson WC, Kris-Etherton PM, et al. Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ß Superfamily Hormones in PCOS. J Clin Endocrinol Metab. 2021. PMID: 32968804. doi:10.1210/clinem/dgaa682

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。